Key Highlights

  • AVITA Medical (ASX:AVH) shares were up 8.52% at $4.33 during the 22 October 2026 session.
  • In its 18 August 2026 announcement, AVITA reported that PermeaDerm met its primary endpoint, with mean cost of $148.70 per %TBSA treated versus $497.10 for allograft.
  • The 40-patient study across 11 U.S. burn centers also reported a 95.7% reduction in preparation time and comparable graft take and wound healing.

AVITA Medical, Inc. (ASX:AVH) shares were up 8.52% at $4.33 during the Trading session on 22 October 2026, at the time of the data at 11:55 am. The broader market was softer: the S&P/ASX 200 stood at 8,774.90, down 0.64% (56.40 points), while the All Ordinaries stood at 8,897.80, down 0.66%. AVITA is a therapeutic acute wound care company, based in Valencia, California, that is dual listed on the ASX and Nasdaq and markets the RECELL skin regeneration system.

About the Company

AVITA Medical, Inc. is listed on NASDAQ under the ticker RCEL and on the Australian Securities Exchange under the ticker AVH. The company is headquartered in Valencia, California, and describes itself as a therapeutic acute wound care company delivering solutions designed to optimise wound healing and accelerate time to patient recovery.

Cary Vance is President and Chief Executive Officer.

Business Overview

AVITA's platform is built around RECELL, which is approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL uses a patient's own skin to create Spray-On Skin at the point of care. Internationally, RECELL and RECELL GO are CE-marked in Europe, have TGA certification in Australia and are listed with Medsafe in New Zealand, and RECELL is PMDA-approved in Japan.

In the U.S., AVITA also holds exclusive Marketing and distribution rights to Cohealyx, a collagen-based dermal matrix, and exclusive Manufacturing and commercial rights to PermeaDerm, a biosynthetic wound matrix.

PermeaDerm-I Study Results

In its announcement dated 18 August 2026, AVITA reported results from PermeaDerm-I, a post-market multicenter randomised controlled trial comparing PermeaDerm with cadaveric allograft for temporary wound coverage before definitive skin grafting. The study enrolled 40 patients across 11 U.S. burn centers, with wounds of up to 30% total body surface area (TBSA) eligible, and followed patients for eight weeks after definitive closure.

The study met its primary endpoint of treatment cost per percent TBSA treated, with statistical significance (p<0.001). Mean treatment cost was $148.70 per 1% TBSA with PermeaDerm versus $497.10 with allograft, a difference of about $348. The company characterised this as a 70% economic advantage.

Clinical Outcomes and Workflow Data

The 18 August 2026 announcement said PermeaDerm reduced preparation time by 95.7% compared with allograft by removing tissue tracking, thawing and meshing, while application time in the operating room was comparable. About 94% of PermeaDerm patients achieved at least 95% graft take one week after autografting, comparable to allograft, and all patients in both groups achieved 95% or greater wound healing by eight weeks.

No adverse events were attributed to PermeaDerm. At final follow-up, all responding investigators and patients reported being satisfied or very satisfied. Secondary endpoints included preparation time, application time, graft take, wound healing, inflammatory profile, adverse events and satisfaction. The trial is registered at ClinicalTrials.gov under NCT06750809.

Related Sector Context

Acute wound care and burn treatment is a segment of the MedTech industry in which temporary coverage products bridge the period between surgical excision and definitive closure. Cadaveric allograft is an established option in that setting, and products are assessed on clinical outcomes, handling requirements and cost to hospitals.

MedTech and healthcare shares can be influenced by clinical data, regulatory decisions and reimbursement factors. On 22 October 2026, the broader market was lower, with the S&P/ASX 200 down 0.64% and the All Ordinaries down 0.66% at 11:55 am, so AVITA's 8.52% gain during the session ran against the direction of the benchmarks.

Risks to Weigh In

The PermeaDerm-I study enrolled 40 patients, and the cost comparison is based on product cost per percent TBSA treated. The announcement does not address broader hospital costs, and results from a single study may not be replicated in wider clinical use.

AVITA's own cautionary note lists factors that could cause results to differ from expectations, including industry market conditions, failure to obtain or maintain regulatory approvals, Supply chain disruptions affecting manufacturing, market penetration of its products and changes in legal or regulatory environments.

Catalysts on Watch

AVITA said it would host a Key Opinion Leader webinar on Tuesday 18 August 2026 at 4:30 p.m. Eastern Time, featuring Dr Anju Saraswat of Atrium Health Wake Forest Baptist Burn Center and Dr Christina Sharon of Baton Rouge General, to review the PermeaDerm-I data and discuss clinical experience with PermeaDerm. A replay was to be posted on the company's investor website.

Beyond that event, the announcement did not set out further dated milestones.

Putting It Together

AVITA's shares were up 8.52% at $4.33 during the 22 October 2026 session, with both major indices lower. The company's 18 August 2026 announcement detailed a randomised study in which PermeaDerm met its cost endpoint and reported comparable graft take and wound healing to allograft. That announcement was made two months before the trading session discussed here.